ArticleJournal of applied toxicology : JAT2026
Biosafety Evaluation of 6,7-Dihydroxy-3-(2-Nitrophenyl)Coumarin in Human Cells.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biosafety Evaluation of 6,7-Dihydroxy-3-(2-Nitrophenyl)Coumarin in Human Cells.Journal of applied toxicology : JAT · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Coumarins are considered a privileged scaffold in medicinal chemistry, as they may interact with biological macromolecules, presenting several pharmacological properties. Their potential makes them an object of study for the evaluation of their safety for humans, which is essential in the design of a potential drug. 6,7-Dihydroxy-3-(2-nitrophenyl)coumarin is a synthetic derivative with antioxidant properties, amongst other biological activities under study. The main goal of this study is to evaluate the potential cytotoxic and genotoxic effects of this molecule in peripheral blood mononuclear cells (PBMCs) and human hepatocellular carcinoma cells (HepG2/C3A). The results obtained for the cytotoxicity assays, evaluated by the resazurin assay, using concentrations between 0.1 and 50 μg/mL, showed that there is no decrease in cell viability for both cell lines. Regarding genotoxic assays, the data obtained by the comet assay and the micronucleus test, up to a concentration of 30 μg/mL, did not show significant DNA damage and/or chromosomal mutations for both cell types. Given these results, it can be concluded that 6,7-dihydroxy-3-(2-nitrophenyl)coumarin, up to a concentration of 30 μg/mL, does not present cytotoxic or genotoxic effects in human cells with and without hepatic metabolism. Considering that this family of coumarins, in general, presents their biological effect at low concentrations (mainly nanomolar range), the results obtained here encourage further studies with this molecule in drug discovery programs. 6,7-Dihydroxy-3-(2-nitrophenyl)coumarin is a new synthetic derivative with antioxidant properties, amongst other biological activities under study. The main goal of this study was to evaluate the potential cytotoxicity and genotoxicity of this molecule in human cells in vitro. Cytotoxicity assays in concentrations between 0.1 and 50 μg/mL showed no decrease in cell viability. Comet assay and the micronucleus test, up to a concentration of 30 μg/mL, did not show genetic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.